Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
What the film says
When a child's brain tumor comes back after surgery, radiation, and chemotherapy, there is usually nothing standard left.
The idea: borrow a treatment that has already done something remarkable in adults.
Many brain tumors carry a surface protein called IL13 receptor alpha 2, which healthy brain does not. City of Hope built T cells with a receptor for it. Given to adults with recurrent glioblastoma, into the fluid around the brain, the cells were safe, and in one man with tumors through his brain and spine, every tumor disappeared for seven months.
This trial brings those cells to children and young adults, aged four to twenty-five, weekly for up to four weeks. Leo Wang leads it. Safety first. Public record; not medical advice.
Sources behind this film
Nothing standard left at recurrence; Children and young adults aged 4–25 whose tumors carry the marker; lymphodepletion then weekly ICV doses up to four cycles; Leo Wang leads; sites in Los Angeles (CHLA) and Michigan (Mott)
Brown CE. N Engl J Med, 2016
IL13Rα2 on many brain tumors, not on healthy brain; Adults with recurrent glioblastoma: intraventricular CAR T; safe; one patient with multifocal disease had complete regression lasting 7.5 months
Brown CE. Clin Cancer Res, 2015
IL13Rα2 on many brain tumors, not on healthy brain
Brown CE. Nat Med, 2024
Adults with recurrent glioblastoma: intraventricular CAR T; safe; one patient with multifocal disease had complete regression lasting 7.5 months
The drug
PRIMARY OBJECTIVE: I. To assess the feasibility and safety of lymphodepleting chemotherapy followed by cellular immunotherapy utilizing IL13Ralpha2-specific hinge-optimized 41BB-co-stimulatory chimeric antigen receptor [CAR] truncated CD19-expressing autologous T-lymphocytes (IL13[EQ]BBzeta/CD19t+ Tn/mem cells) administered by intraventricular (ICV) delivery for pediatric participants with IL13Ralpha2+ recurrent/refractory brain tumors. SECONDARY OBJECTIVES: I.
To describe persistence and expansion of CAR T cells in peripheral blood (PB) and cerebrospinal (CSF). II. To describe cytokine levels (PB, and CSF) over the study period. III. In research participants who receive the full schedule of 4 CAR T cell cycles: IIIa. To estimate 6-month progression free survival (PFS) rate per disease. IIIb. To estimate disease response rates per disease. IIIc. To estimate 1-year overall survival rate per disease. IV.
The study
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherapy (IL13(EQ)BBzeta/CD19t+ T cells) are brain-tumor specific cells that may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Chemotherapy drugs, such as as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many patients with brain tumor respond to treatment, but then the tumor starts to grow again. Giving chemotherapy in combination with cellular immunotherapy may kill more tumor cells and improve the outcome of treatment.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.